Jenkins Annalisa 4

What Happened Annalisa Jenkins, a director of Skye Bioscience (SKYE), received a derivative award of 75,000 stock options on March 31, 2026. The Form 4 reports an acquisition amount of $0.00 for the award (derivative instrument). This was a grant/award (not a purchase or sale).

Key Details

• Transaction date: 2026-03-31; Form 4 filed 2026-04-02 (appears timely).
• Instrument: Derivative award (stock option) for 75,000 shares; reported acquisition price $0.00.
• Vesting: Vests in equal monthly installments over a one-year period beginning March 31, 2026 (see footnote F1).
• Shares owned after transaction: not specified in the filing.
• Filing code: A (award/grant); no 10b5-1 plan, tax-withholding, or cashless exercise noted.

Context This was an option grant to a director—a common form of equity compensation meant to align long-term interests. As an award (not a purchase or sale), it does not reflect an immediate buy/sell decision. The options vest monthly over the next year before they become exercisable per the disclosed schedule.